Creating a responsible organisation that delivers VALUE
From being a standalone Antibiotic Manufacturer, now becoming a differentiated Antibiotic and Non-Antibiotic API Manufacturer.
Parabolic Drugs Limited, founded in 1996, is engaged in the manufacturing of APIs and API intermediates including contract manufacturing. In the year 2011, the company has stepped up in the value chain by foraying into the domestic formulations.
Today Parabolic has four large scale facilities, three state of the art manufacturing plants at Derabassi, Chachhrauli and Panchkula for over 50 API and API intermediates across antibiotics and non-antibiotic therapies and a Custom Synthesis and R&D centre at Barwala, Haryana.
The company is surging ahead with the right set of drivers 96 backward and forward integration, world class infrastructure, R&D strengths, diversified product basket across different therapeutic segments and Intellectual Property Rights in the form of DMFs, and Patents for novel processes.
Achieving highest International quality standards
Your company hasa distinctive recognition of being one of the few pharmaceutical companies certified by the European GMP. With the audit approvals of over 40 pharmaceutical companies, your company foresees the regulatory approvals through other international agencies including the Japanese PMDA and the USFDA.
Horizontal growth through the diversified basket
Our foray into the non-antibiotic space places us in an unique position to be one of the largest API companies with a multiple range of products across varied therapies. The transition towards becoming a multi-specialty API manufacturer is going to de-risk the company’s sizable reliance on antibiotics, where a couple of products have got commoditized and margins have been affected by competition. We believe that the new life style drugs will drive margins and hence profitability.
Growth through progress in Research and Development
The research team at Parabolic continues to drive the business by creating a grid of niche molecules and working on the next generation of products. Going forward, the inhouse R&D team would continue to drive process research and find innovative ways to reduce cost and build competitiveness.
Vertical integration for value maximization
The company moved up the value chain by launching its finished dosage business. The company successfully created a basket of over 150 products across multiple therapeutic classes in different dosage forms. The dosage business will substantially add to the value of the company in the forthcoming years. The thrust for the formulations business would be through two verticals - the domestic formulations through our division ‘Nucleus’ and the International Formulations division.
Parabolic Drugs will strive to continue the consistent growth that it has displayed over the last couple of years with increased commitment and focus on the bottom line. The company will achieve to realize this through operational efficiencies, improvements and innovation across production, marketing, research and other capabilities. The rationale is just not to create an organization of growth and profits, but to create a responsible organization which drives its business with excellence and sustainability.
Focus on Regulated Markets
Diversification into new business verticals
High GMP Standards
Investment in R&D
Headway in the Contract manufacturing Space
Leveraging on the world class infrastructure with large capacities, a cost arbitrage in respect to competition, your company is geared to provide integrated solutions from route selection, process development, and optimization to different innovators and generic companies of the globe. It will continue to develop the competitive advantage it already possesses in the area of contract manufacturing and research to be able to grow and add scale to this segment of business.